Cardiff Lexington Announces Fourth Quarter and Full Year 2025 Financial Results

Rhea-AI Summary

Cardiff Lexington (OTCQB: CDIX) reported full year 2025 results: revenue $11.5M (up 39.5% YoY) and gross profit $7.2M (62.5% margin). Operating income was $1.1M while net loss was $(5.5M) due largely to $6.8M interest expense. The company executed a 1-for-3 reverse split and announced a March 16, 2026 investor webcast.

Management cited higher patient volumes, a shift to higher-value surgical procedures, expanded operations in Florida and Georgia, and talent additions to support growth and a planned uplisting.

Positive

• Total revenue +39.5% to $11.5M in FY2025
• Gross profit of $7.2M representing a 62.5% margin
• Operating income of $1.1M in FY2025 (9.5% of revenue)

Negative

• Net loss of $(5.5M) in FY2025
• Interest expense rose to $6.8M in FY2025, materially increasing losses
• Year-end cash balance of $319,000 may pressure near-term liquidity

News Market Reaction – CDIX

-3.27%

1 alert

-3.27% News Effect

On the day this news was published, CDIX declined 3.27%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

FY 2025 revenue: $11.5M FY 2024 revenue: $8.3M FY 2025 gross profit: $7.2M (62.5%) +5 more

8 metrics

FY 2025 revenue $11.5M Full year 2025 total revenue, up 39.5% vs 2024

FY 2024 revenue $8.3M Full year 2024 total revenue baseline for YoY comparison

FY 2025 gross profit $7.2M (62.5%) Full year 2025 gross profit and margin

FY 2024 gross profit $4.4M (53.6%) Full year 2024 gross profit and margin

FY 2025 operating income $1.1M (9.5%) Operating income from full year 2025 vs prior-year loss

FY 2025 net loss $(5.5M) Full year 2025 net loss vs $(3.3M) in 2024

FY 2025 interest expense $(6.8M) Interest expense in 2025 vs $(3.0M) in 2024

FY 2025 adjusted EBITDA $1.8M Non-GAAP adjusted EBITDA for full year 2025

Market Reality Check

Price: $3.40 Vol: Volume 2,200 vs 20-day av...

normal vol

$3.40 Last Close

Volume Volume 2,200 vs 20-day average 3,118 (relative volume 0.71x), suggesting muted pre-news activity. normal

Technical Price at $3.36, trading below 200-day MA at $6.37, indicating a longer-term downtrend ahead of this earnings.

Peers on Argus

CDIX was up 3.38% pre-news. Peers were mixed: NUMIF up 6.4%, XCRT up 8.12%, VLXC...

CDIX was up 3.38% pre-news. Peers were mixed: NUMIF up 6.4%, XCRT up 8.12%, VLXC down 23.08%, others flat. The momentum scanner flagged no sector-wide move, pointing to company-specific dynamics.

Previous Earnings Reports

5 past events · Latest: Nov 14 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 14	Q3 2025 earnings	Positive	-57.7%	Substantial Q3 revenue and margin improvement versus prior-year quarter.
Aug 26	Q2 2025 earnings	Positive	+8.0%	Strong Q2 revenue growth, margin gains and higher income from operations.
Jul 29	Q2 2025 call notice	Neutral	+249.3%	Announcement of timing and access details for Q2 2025 results call.
May 13	Q1 2025 earnings	Positive	-56.1%	Strong Q1 revenue, gross profit and operating income growth year-over-year.
Mar 17	FY 2024 results	Positive	-56.1%	Q4 2024 revenue growth, margin strength and footprint expansion despite challenges.

Pattern Detected

Earnings and related communications have produced volatile and often contrarian moves, with several strong financial updates followed by sharp declines.

Recent Company History

Across the last five earnings-tagged events from Mar 17, 2025 through Nov 14, 2025, Cardiff Lexington reported rapid revenue growth and margin expansion at Nova Ortho and Spine, frequently highlighting improved income from continuing operations and rising gross profit. Despite this, three events with strong fundamentals were followed by large negative price reactions, while two—including a Q2 2025 earnings beat and an earnings call scheduling release—saw sharp gains. Today’s full-year 2025 results continue the theme of growth paired with ongoing net losses and interest expense pressure.

Historical Comparison

+17.5% avg move · This earnings release follows five prior earnings-tagged updates that averaged a 17.46% next-day mov...

earnings

+17.5%

Average Historical Move earnings

This earnings release follows five prior earnings-tagged updates that averaged a 17.46% next-day move, illustrating historically high volatility around Cardiff Lexington’s financial reports.

Earnings releases from Q1 through Q3 2025 showed accelerating revenue, stronger gross margins and improved operating income at Nova Ortho and Spine, while net losses persisted due to interest expense. The current full-year 2025 report extends this pattern with higher revenue and gross profit but a larger net loss, reflecting ongoing financing costs alongside operational expansion.

Market Pulse Summary

This announcement reports full-year 2025 revenue of $11.5M with higher gross profit and operating in...

Analysis

This announcement reports full-year 2025 revenue of $11.5M with higher gross profit and operating income, but also a larger net loss of $(5.5M) mainly from increased interest expense. It follows a year of quarterly earnings that paired strong operating trends with persistent losses. Investors may watch future filings for changes in debt costs, details of any equity offerings, and progress on the planned uplisting as key indicators of financial flexibility.

Key Terms

gaap, non-gaap adjusted revenue, non-gaap adjusted ebitda, ebitda, +3 more

7 terms

gaap financial

"full year revenue increased 39.5% on a GAAP basis in 2025 compared with 2024"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

non-gaap adjusted revenue financial

"Non-GAAP adjusted revenue, which excludes this one-time adjustment to revenue"

Revenue reported after a company removes or alters certain items that standard accounting rules would normally include, such as one-time gains or losses, currency effects, or contract adjustments. Investors use it as a clearer picture of the business’s recurring sales — like wiping mud off a window to see the view — but because companies choose which items to exclude, it can be subjective and should be compared with the standard accounting revenue for a balanced view.

non-gaap adjusted ebitda financial

"Non-GAAP adjusted EBITDA, which excludes interest expense, was $1.8 million"

Non-GAAP adjusted EBITDA is a measure of a company's profitability that shows earnings before interest, taxes, depreciation, and amortization, with certain adjustments made to exclude irregular or non-recurring expenses and income. It provides a clearer picture of ongoing operational performance by filtering out items that might distort the core business results. Investors use it to better compare how well different companies are performing without the noise of one-time events.

ebitda financial

"Non-GAAP adjusted EBITDA, which excludes interest expense, was $1.8 million"

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It measures a company's profitability by focusing on the money it makes from its core operations, ignoring expenses like taxes and accounting adjustments. Investors use EBITDA to compare how well different companies are performing financially, as it provides a clearer picture of operational success without the influence of financial structure or accounting choices.

sg&a financial

"increased SG&A expense of $5.3 million, or 46.2% of revenue"

SG&A stands for Selling, General, and Administrative expenses. It includes the costs a company spends on selling products, running the business day-to-day, and managing staff, like advertising, rent, and salaries. These expenses matter because they affect how much profit a company can make from its sales.

reverse split financial

"execution of a 1-for-3 reverse split as a part of our planned uplisting"

A reverse split is when a company reduces the number of its outstanding shares by combining several existing shares into one new share, so the price per share rises proportionally while the company’s overall value stays the same. Investors care because it can make a stock appear more respectable or meet exchange rules — like turning many small coins into a single larger bill — but it can also signal financial trouble and often affects trading liquidity and investor perception.

line of credit financial

"fees charged on the number of existing purchases and claims under the Company's line of credit"

A line of credit is a flexible borrowing arrangement that lets a company draw money up to a preset limit, repay it, and borrow again as needed—similar to a business credit card or an emergency tap on a savings account. It matters to investors because it shows how a firm manages short-term cash needs and growth funding without taking a single large loan; access, cost, and attached conditions can affect liquidity, interest expenses and financial risk.

AI-generated analysis. Not financial advice.

• 39.5% increase in FY25 total revenue to $11.5 million compared to FY 2024

• 62.7% increase in FY25 gross profit to $7.2 million compared to FY 2024

• $1.1 million in income from continuing operations in FY 2025

• Strengthening operational team and capital structure to position Company for next phase of growth

LEXINGTON, KY / ACCESS Newswire / March 16, 2026 / Cardiff Lexington Corporation (OTCQB:CDIX) today announced financial results for the fourth quarter and full year ended December 31, 2025.

Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "2025 was a year of strong strategic execution as we continued to enhance our Nova Ortho and Spine footprint and offerings while making meaningful progress on our long-term goals. Notably, full year revenue increased 39.5% on a GAAP basis in 2025 compared with 2024, supported by our operations in numerous diverse locations throughout Florida and Georgia where we are seeing strong demand for our services. Operationally, we've shifted our focus to more higher value surgical procedures, and our patient volumes continue to increase, with an average of between 270 and 375 patients treated per month across all our locations.

"During the fourth quarter, we strengthened the Nova Ortho and Spine team with the addition of leading healthcare talent and entered a strategic partnership with Doctors' Memorial Hospital in Perry, Florida to bring our leading services to patients in this area of the state. Subsequent to the close of the quarter, we improved our capital structure with the execution of a 1-for-3 reverse split as a part of our planned uplisting to a major US stock exchange. We believe this will strengthen our capital markets profile and enhance our visibility, liquidity, and access to capital to support our anticipated growth as we continue to bring our world-class care to an underserved patient population," Mr. Cunningham concluded.

Full Year 2025 Financial Highlights

Total revenue increased 39.5% to $11.5 million compared with $8.3 million in full year 2024, primarily related to higher patient volume and a shift to more higher value surgical procedures throughout the year. Revenue in full year 2024 included one-time adjustments of $2.8 million. Non-GAAP adjusted revenue, which excludes this one-time adjustment to revenue, was $11.1 million for full year 2024.

Gross profit increased to $7.2 million, or 62.5% of total revenue, compared with $4.4 million, or 53.6% of total revenue in full year 2024.

Total operating expenses increased to $6.1 million compared with $4.6 million in full year 2024, primarily related to increased SG&A expense of $5.3 million, or 46.2% of revenue, compared with $4.1 million, or 49.1% of revenue, for the full year 2024.

Operating income increased to $1.1 million, or 9.5% of total revenue, compared with operating loss of $(193,000), or (2.3%) of total revenue, in full year 2024.

Net loss in full year 2025 was $(5.5 million) compared with net loss of $(3.3 million) in full year 2024. Included in full year 2025 was interest expense of $(6.8 million) compared with interest expense of $(3.0 million) in full year 2024. This increase in interest expense is primarily related to increases in initial and incremental fees charged on the number of existing purchases and claims under the Company's line of credit.

Non-GAAP adjusted EBITDA, which excludes interest expense, was $1.8 million compared with non-GAAP adjusted EBITDA of $2.1 million in full year 2024, which excludes interest expense and the change in accounting estimate of the billing realization rate recognized in third quarter 2024.

Fourth Quarter 2025 Financial Results

Total revenue was $2.8 million compared with 3.1 million in the fourth quarter of 2024. The decrease is primarily attributed to normal variances around the collection cycle timeframe on accounts receivables, which is typically between 12 and 24 months, as well as the timing of the 2025 holiday season, which resulted in significantly reduced patient volume over the two-week period around Christmas and New Years.

Gross profit was $1.8 million, or 63.5% of total revenue, compared with $2.0 million, or 64.8% of total revenue in the fourth quarter of 2024.

Total operating expenses increased to $2.5 million compared with $1.7 million in the fourth quarter of 2024, primarily related to increased stock compensation expense of $616,000 and SG&A expense of $1.8 million, or 66.0% of revenue in the fourth quarter of 2025, compared with $1.4 million, or 46.2% of revenue in the fourth quarter of 2024.

Loss from continuing operations was $(696,000), or (25.1%) of total revenue, in the fourth quarter of 2025, compared with income from continuing operations of $332,000, or 10.6% of total revenue, in the fourth quarter of 2024.

Net loss in the fourth quarter of 2025 was $(2.7 million) compared with net loss of $(910,000) in the fourth quarter of 2024. Included in net loss for the three months ended December 31, 2025, was interest expense of $(2.2 million) compared with interest expense of $(1.2 million) in the fourth quarter of 2024. This increase in interest expense is related to increases in initial and incremental fees charged on the number of existing purchases and claims under the Company's line of credit.

Non-GAAP adjusted EBITDA, which excludes interest expense, was a loss of $(79,000) compared with non-GAAP adjusted EBITDA of $579,000 in the fourth quarter of 2024.

Balance Sheet

Cash totaled $319,000 as of December 31, 2025.

Total assets increased 21.6% to $29.1 million as of December 31, 2025.

Conference Call

Cardiff Lexington will hold a conference call and webcast for investors today, March 16, 2026, at 11:00 a.m. Eastern Time.

Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 860308. The call and the accompanying slide deck will also be webcast at:

https://www.webcaster5.com/Webcast/Page/3131/53650

The conference call and slide deck may also be accessed via the Investor Relations page of the Company's website at https://investor.cardifflexington.com/overview/default.aspx. Please allow extra time prior to the call to visit the site.

An online archive of the webcast will be available on the Investor Relations page of the Company's website following the call at https://investor.cardifflexington.com/overview/default.aspx. A replay of the conference call will be available one hour after completion of the call until Monday, March 30, 2026, by dialing (877) 481-4010 and international participants should dial (919) 882-2331. All callers must use access code 53650 to access the replay.

-----

About Cardiff Lexington Corporation:

Cardiff Lexington Corporation (OTCQB:CDIX) is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. The Company's partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance.

All current revenue is derived from Nova Ortho and Spine, LLC, which operates a network of regional specialty and ancillary orthopedic care centers across Florida and Georgia. These facilities provide traumatic injury patients with comprehensive diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultations.

For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/

FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.

Use of Non-GAAP Financial Measures

Cardiff Lexington Corporation prepares its consolidated financial statements in accordance with United States generally accepted accounting principles ("GAAP"). In addition to GAAP disclosures, this document contains financial information and measures considered to be "non-GAAP". These non-GAAP measures can be used in order to gain a more complete and accurate understanding of the Company's financial condition and results. Non-GAAP financial measures should be considered in conjunction with, and not as a substitute to GAAP financial measures.

Cardiff Lexington Investor Relations
investorsrelations@cardifflexington.com
(800) 628-2100 ext. 705

or

IMS Investor Relations
cardifflexington@imsinvestorrelations.com
(203) 972-9200

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2025, AND 2024

		For the Three Months Ended								For the Twelve Months Ended
		December 31,				December 31,				December 31,				December 31,
		2025				2024				2025				2024
Total revenue		$	2,772,263			$	3,120,710			$	11,535,577			$	8,270,126
Total cost of sales			1,011,387				1,099,863				4,329,330				3,841,628
Gross profit			1,760,876				2,020,847				7,206,247				4,428,498
Operating expenses
Depreciation expense			762				3,365				5,652				13,461
Loss on disposal of fixed assets			0				0				12,593				0
Stock compensation expense			615,787				244,500				754,475				544,725
Selling, general and administrative			1,840,631				1,440,835				5,332,941				4,063,816
Total operating expenses			2,457,180				1,688,700				6,105,661				4,622,002
(Loss) income from continuing operations			(696,304	)			332,147				1,100,586				(193,504	)
Other (expense) income:
Other expense			0				(642	)			(22,147	)			(5,362	)
Gain on debt refinance, forgiveness and settlement			0				0				0				78,834
Penalties and fees			0				0				(1,500	)			(1,330	)
Interest expense			(2,228,102	)			(1,241,847	)			(6,822,816	)			(3,045,504	)
Amortization of debt discounts			0				0				0				(24,821	)
Total other expense			(2,228,102	)			(1,242,489	)			(6,846,463	)			(2,998,183	)
Net loss before discontinued operations			(2,924,406	)			(910,342	)			(5,745,877	)			(3,191,687	)
Income (loss) from discontinued operations			238,285				0				238,285				(111,312	)
Net loss		$	(2,686,121	)		$	(910,342	)		$	(5,507,592	)		$	(3,302,999	)

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF DECEMBER 31, 2025, AND DECEMBER 31, 2024

		December 31,				December 31,
		2025				2024
ASSETS
Current assets
Cash		$	318,535			$	1,188,185
Accounts receivable-net			22,070,954				15,934,490
Prepaid and other current assets			203,876				89,901
Total current assets			22,593,365				17,212,576
Property and equipment, net			2,953				21,198
Land			540,000				540,000
Goodwill			5,666,608				5,666,608
Right of use - assets			214,858				406,950
Due from related party			4,979				4,979
Other assets			64,182				73,368
Total assets			29,086,945				23,925,679
LIABILITIES, MEZZANINE EQUITY AND DEFICIENCY IN STOCKHOLDERS' (DEFICIT)/EQUITY
Current liabilities
Accounts payable and accrued expense			1,760,765				1,379,760
Accrued expenses - related parties			4,645,826				4,553,057
Accrued interest			707,574				429,200
Right of use - liability			178,524				223,330
Notes payable - current portion			125,774				312,180
Notes payable related parties			1,085,703				0
Line of credit			17,209,908				8,645,991
Convertible notes payable, net of debt discounts of $131,705 and $24,821, respectively			118,295				105,000
Net liabilities of discontinued operations			0				238,285
Total current liabilities			25,832,369				15,886,803
Other liabilities
Notes payable			138,773				251,725
Operating lease liability - long term			42,976				185,877
Total liabilities			26,014,118				16,324,405
Mezzanine equity
Redeemable Series N Senior Convertible Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value $4.00, 1,037,311 and 921,636 shares issued and outstanding at December 31, 2025 and 2024, respectively			3,802,010				3,339,317
Redeemable Series X Senior Convertible Preferred Stock - 5,000,000 shares authorized, $0.001 par value, stated value of $4.00 par value; 438,388 and 397,464 shares issued and outstanding at December 31, 2025 and 2024, respectively			1,740,478				1,576,788
Total Mezzanine Equity			5,542,488				4,916,105
Stockholders' (deficit)/equity
Series B Preferred Stock - 3,000,000 shares authorized, $0.001 par value, stated value of $4.00, 0 and 1,279,867 shares issued and outstanding at December 31, 2025 and 2024, respectively			0				5,119,468
Series C Preferred Stock - 500 shares authorized, $0.001 par value, stated value of $4.00, 0 and 74 shares issued and outstanding at December 31, 2025 and 2024, respectively			0				296
Series E Preferred Stock - 1,000,000 shares authorized, $0.001 par value, stated value $4.00, 0 and 175,375 shares issued and outstanding at December 31, 2025 and 2024, respectively			0				701,500
Series F-1 Preferred Stock - 50,000 shares authorized, $0.001 par value, stated value $4.00, 3,875 shares issued and outstanding at December 31, 2025 and 2024			15,500				15,500
Series I Preferred Stock - 15,000,000 shares authorized, $0.001 par value, stated value $4.00, 0 and 10,469,092 issued and outstanding at December 31, 2025 and 2024, respectively			0				41,876,368
Series L Preferred Stock - 400,000 shares authorized, $0.001 par value, stated value $4.00, 319,493 shares issued and outstanding at December 31, 2025 and 2024			1,277,972				1,277,972
Series Y Senior Convertible Preferred Stock - 1,500,000 shares authorized, $0.001 par value, stated value of $4.00, 1,067,878 and 979,125 shares issued and outstanding at December 31 2025 and 2024, respectively			4,271,512				3,916,500
Common Stock; 300,000,000 shares authorized, $0.001 par value; 13,701,698 and 15,300,475 shares issued and outstanding at December 31, 2025 and 2024, respectively			13,702				15,300
Additional paid-in capital			72,021,848				22,711,350
Unearned stock compensation			(579,215	)			0
Accumulated deficit			(79,490,980	)			(72,949,085
Total stockholders' (deficit)/equity			(2,469,661	)			2,685,169
Total liabilities, mezzanine equity and stockholders' equity			29,086,945				23,925,679

 

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2025, AND 2024
(Unaudited)

The following table reconciles Net (loss) income before discontinued operations (a GAAP measure) to EBITDA (a non-GAAP measure)

		For the Three Months Ended								For the Twelve Months Ended
		December 31,								December 31,
		2025				2024				2025				2024
EBITDA (1)
Net loss before discontinued operations		$	(2,924,406	)		$	(910,342	)		$	(5,745,877	)		$	(3,191,687	)
Add:
Interest			2,228,102				1,241,847				6,822,816				3,045,504
Taxes			0				0				0				0
Depreciation			762				3,365				5,652				13,461
Amortization			0				0				0				24,821
EBITDA (1)		$	(695,542	)		$	334,870			$	1,082,591			$	(107,901	)
Adjusted EBITDA (2)
EBITDA		$	(695,542	)		$	334,870			$	1,082,591			$	(107,901	)
Add:
Change in estimate for settlement realization rate			0				0				0				1,650,474
Stock compensation expense for shares issued			615,787				244,500				754,475				544,725
Adjusted EBITDA (2)		$	(79,755	)		$	579,370			$	1,837,066			$	2,087,298
Adjusted EBITDA excluding other non-recurring costs (3)
Adjusted EBITDA		$	(79,755	)		$	579,370			$	1,837,066			$	2,087,298
Add:
Scaling and restructuring costs for business growth			473,804				39,752				485,480				220,053
Acquisition related costs			59,256				30,581				230,771				30,581
Adjusted EBITDA excluding other non-recurring costs (3)		$	453,305			$	649,702			$	2,553,317			$	2,337,932

(1) EBITDA is a non-GAAP financial measure defined as Earnings Before Interest, Income Tax, Depreciation and Amortization.
(2) Adjusted EBITDA is a non-GAAP financial measure that is the sum of EBITDA plus non-recurring and non-cash charges.
(3) Adjusted EBITDA excluding other non-recurring costs is a non-GAAP financial measure that is the sum of Adjusted EBITDA plus other non-recurring costs.

 

CARDIFF LEXINGTON CORPORATION AND SUBSIDIARIES
RECONCILIATION OF REVENUE FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2025, AND 2024

The following table reconciles Revenue (a GAAP financial measure) to Adjusted Revenue (non-GAAP financial measures)
		For the Three Months Ended December 31,						For the Twelve Months Ended December 31,
		2025			2024			2025			2024
GAAP Revenue		$	2,772,263		$	3,120,710		$	11,535,577		$	8,270,126
Adjustments to Claim Settlement Realization Rate			-			-			-			2,849,629
Non-GAAP Adjusted Revenue		$	2,772,263		$	3,120,710		$	11,535,577		$	11,119,755

SOURCE: Cardiff Lexington Corporation

View the original press release on ACCESS Newswire

FAQ

What were Cardiff Lexington (CDIX) full year 2025 revenues and growth rate?

CDIX reported $11.5 million in total revenue for full year 2025, a 39.5% increase year-over-year. According to the company, growth was driven by higher patient volumes and a shift to higher-value surgical procedures across Florida and Georgia.

Why did Cardiff Lexington (CDIX) report a net loss in FY2025 despite revenue growth?

CDIX posted a FY2025 net loss of $(5.5M), primarily due to higher interest expense. According to the company, interest expense increased to $6.8M, which materially contributed to the year-over-year net loss.

How did Cardiff Lexington (CDIX) perform in profitability metrics in 2025?

Gross profit increased to $7.2M, yielding a 62.5% gross margin in FY2025. According to the company, operating income was $1.1M, reflecting improved operational mix and higher-value procedures.

What corporate action did Cardiff Lexington (CDIX) take to improve its capital structure?

CDIX executed a 1-for-3 reverse stock split subsequent to year-end as part of an uplisting plan. According to the company, the split aims to strengthen its capital markets profile, visibility, liquidity, and access to capital.

What was Cardiff Lexington's (CDIX) cash and asset position at year-end 2025?

As of December 31, 2025, CDIX reported cash of $319,000 and total assets of $29.1M. According to the company, assets grew 21.6% year-over-year while cash remained modest relative to operating needs.

When and how can investors access Cardiff Lexington's (CDIX) March 16, 2026 conference call?

The CDIX investor webcast and call occurred March 16, 2026 at 11:00 a.m. ET, with a live dial-in and a webcast link. According to the company, a replay archive is available on the investor relations website through March 30, 2026.